What does “biosimilars in Southeast Asia” usually mean?
In Southeast Asia, biosimilars are follow-on versions of already-approved biologic medicines (for example, antibodies or growth factors) that have demonstrated similarity in quality, clinical performance, and safety to the original reference product. Because biologics are complex, approvals typically require head-to-head comparative evidence and manufacturing quality checks rather than simple “generic-like” substitution.[1]
How are biosimilars approved in different Southeast Asian countries?
Southeast Asia does not have one single pathway; each country regulates biosimilars under its own medicines authority:
- Indonesia: Uses approval pathways for biosimilars under its national regulatory framework, coordinated through BPOM.
- Malaysia: Biosimilars are regulated through the National Pharmaceutical Regulatory Agency (NPRA) within the Ministry of Health framework.
- Thailand: Regulates biosimilars through the Thai FDA.
- Philippines: Regulates through the FDA Philippines.
- Vietnam: Regulates through the Vietnam Ministry of Health / Department of Drug Administration.
- Singapore: Regulates through the Health Sciences Authority (HSA).
In practice, companies often align submissions with international “comparability” expectations (quality, nonclinical, clinical) to meet local requirements.[1][2]
Which products are most common for biosimilars in the region?
Across many markets globally (and commonly in Southeast Asia), early biosimilar uptake tends to focus on high-volume biologics such as:
- Oncology monoclonal antibodies
- Supportive-care biologics (e.g., epoetins, filgrastim/pegfilgrastim-style growth factors)
The specific mix varies by country depending on tender practices, hospital formularies, and how quickly regulators and payers adopt new biosimilar launches.
How quickly are biosimilars being adopted, and what drives uptake?
Adoption often depends less on regulatory approval speed alone and more on:
- Hospital procurement/tender rules (public vs private market behavior)
- Physician confidence and local prescribing guidance
- Pricing and reimbursement coverage
- Switching policies (whether patients can be switched from the reference biologic to the biosimilar after initiation)
Even with regulatory approval, switching frameworks and procurement decisions can strongly influence real-world uptake.
Are there rules about switching or interchangeability?
In many countries, biosimilars are approved as “biosimilars,” but national guidance on automatic substitution/interchangeability can be stricter than for generics. Some markets allow substitution under specific conditions; others restrict it to prescriber-led changes. The exact details vary by country and may evolve as regulators issue further guidance.[2]
What are the biggest barriers companies face in Southeast Asia?
Common commercial and operational constraints include:
- Country-by-country regulatory submission differences (even if they are broadly similar in scientific expectations)
- Patent and exclusivity barriers in each market
- Supply and manufacturing qualification requirements
- Pricing and reimbursement uncertainty across public and private payers
- Tender cycles that can delay adoption even after approval
Can biosimilars enter before exclusivity ends?
Generally, biosimilar development and regulatory submission timelines are planned around patent and data exclusivity periods. However, the exact “can we file/approve when” depends on each country’s patent laws and regulatory mechanisms. The practical outcome is that launch timing often follows exclusivity or patent clearance, even if regulatory requirements could technically be met earlier.
Are Southeast Asian regulators harmonizing their approach?
Many Southeast Asian regulators and stakeholders use international scientific principles for biosimilar comparability (quality, nonclinical, clinical) rather than inventing entirely separate frameworks. That helps reduce duplication, but local dossier requirements and legal constraints still differ.[1][2]
Where do people look for the latest biosimilar availability?
Searches usually focus on:
- National drug registers/approvals for each country’s regulator
- Hospital formulary lists and tender award announcements
- Biosimilar company product pages that map to country launches
If you tell me which country (e.g., Indonesia vs Singapore) and which medicine (e.g., adalimumab, infliximab, trastuzumab, filgrastim), I can narrow this to the most relevant approvals, uptake patterns, and practical market status.
---
Sources
- https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/biosimilar-products
- https://www.who.int/publications-detail-redirect/9789241507787